Resolving pathobiological mechanisms relating to Huntington disease: Gait, balance, and involuntary movements in mice with targeted ablation of striatal D1 dopamine receptor cells

Neurobiology of Disease

Volumn 62, Issue , 2014, Pages 323-337

  Kim, Hyun Ah ^a   Jiang, Luning ^a   Madsen, Heather ^a   Parish, Clare L ^a   Massalas, Jim ^a   Smardencas, Arthur ^a   O'Leary, Claire ^a,b,d   Gantois, Ilse ^a   O'Tuathaigh, Colm ^b,e   Waddington, John L ^b   Ehrlich, Michelle E ^c   Lawrence, Andrew J ^a   Drago, John ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

D1 dopamine receptor; Huntington disease; Striatum

Indexed keywords

DOPAMINE 1 RECEPTOR; ENKEPHALIN; MESSENGER RNA; NEUROPEPTIDE GAMMA; PROENKEPHALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ANXIETY DISORDER; ARTICLE; ASTROCYTOSIS; BEHAVIOR DISORDER; BODY EQUILIBRIUM; BRAIN ATROPHY; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GAIT; GAIT DISORDER; HUNTINGTON CHOREA; INTERNEURON; INVOLUNTARY MOVEMENT; MALE; MOOD DISORDER; MOTOR DYSFUNCTION; MOUSE; MOUSE MUTANT; NONHUMAN; OROFACIAL DYSKINESIA; PRIORITY JOURNAL; PSYCHOSIS; UPREGULATION; WEIGHT REDUCTION;

D1 DOPAMINE RECEPTOR; HUNTINGTON DISEASE; STRIATUM;

ANIMALS; BRAIN; CELL COUNT; CORPUS STRIATUM; DYSKINESIAS; FEMALE; GAIT; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; POSTURAL BALANCE; RECEPTORS, DOPAMINE D1;

EID: 84887322746     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.09.015     Document Type: Article

References (49)

1. Albin R., et al. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann. Neurol. 1990, 27:357-365.
2. Albin R.L., et al. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol. 1992, 31:425-430.
3. Alexander G.E., et al. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 1986, 9:357-381.
4. Anderson K.D., Reiner A. Immunohistochemical localization of DARPP-32 in striatal projection neurons and striatal interneurons: implications for the localization of D1-like dopamine receptors on different types of striatal neurons. Brain Res. 1991, 568:235-243.
5. Babovic D., et al. Age-related behavioural phenotype and cellular characterisation of mice with progressive ablation of D1 dopamine receptor-expressing cells. Behav. Brain Res. 2010, 206:78-87.
6. Bateup H.S., et al. Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proc. Natl. Acad. Sci. 2010, 107:14845-14850.
7. Bilney B., et al. Evidence for a disorder of locomotor timing in Huntington's disease. Mov. Disord. 2005, 20:51-57.
8. Bogush A., et al. DARPP-32 genomic fragments drive Cre expression in postnatal striatum. Genesis 2005, 42:37-46.
9. Buffo A., et al. Origin and progeny of reactive gliosis: a source of multipotent cells in the injured brain. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:3581-3586.
10. Cannizzaro C., et al. Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease. Mol. Brain Res. 2003, 110:169-176.
11. Chen Y., Swanson R.A. Astrocytes and brain injury. J. Cereb. Blood Flow Metab. 2003, 23:137-149.
12. Davalos D., et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat. Neurosci. 2005, 8:752-758.
13. Dissing-Olesen L., et al. Axonal lesion-induced microglial proliferation and microglial cluster formation in the mouse. Neuroscience 2007, 149:112-122.
14. Drago J., et al. Targeted expression of a toxin gene to D1 dopamine receptor neurons by Cre-mediated site-specific recombination. J. Neurosci. 1998, 18:9845-9857.
15. Durieux P.F., et al. D2R striatopallidal neurons inhibit both locomotor and drug reward processes. Nat. Neurosci. 2009, 12:393-395.
16. Durieux P.F., et al. Differential regulation of motor control and response to dopaminergic drugs by D1R and D2R neurons in distinct dorsal striatum subregions. EMBO J. 2012, 31:640-653.
17. Feigin A., et al. Functional decline in Huntington's disease. Mov. Disord. 1995, 10:211-214.
18. File S.E., et al. Striking changes in anxiety in Huntington's disease transgenic mice. Brain Res. 1998, 805:234-240.
19. Gantois I., et al. Ablation of D1 dopamine receptor-expressing cells generates mice with seizures, dystonia, hyperactivity, and impaired oral behavior. PNAS 2007, 104:4182-4187.
20. Ginovart N., et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997, 120:503-514.
21. Graveland G., et al. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985, 227:770-773.
22. Hefter H., et al. Impairment of rapid movement in Huntington's disease. Brain 1987, 110:585-612.
23. Kerkerian L., et al. Pharmacological characterization of dopaminergic influence on expression of neuropeptide Y immunoreactivity by rat striatal neurons. Neuroscience 1988, 26:809-817.
24. Koller W., Trimble J. The gait abnormality of Huntington's disease. Neurology 1985, 35:1450-1454.
25. Marsden C.D. Drug treatment of diseases characterized by abnormal movements. Proc. R. Soc. Med. 1973, 66:871-873.
26. Midgley L.P., et al. Dynamic dopaminergic regulation of neuropeptide Y systems in discrete striatal and accumbens regions. Eur. J. Pharmacol. 1994, 251:191-199.
27. Naver B., et al. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse. Neuroscience 2003, 122:1049-1057.
28. Nimmerjahn A., et al. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
29. Ouimet C.C., et al. Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res. 1998, 808:8-12.
30. Padungchaichot P., et al. Early direct and transneuronal effects in mice with targeted expression of a toxin gene to D1 dopamine receptor neurons. Neuroscience 1999, 95:1025-1033.
31. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press. 2nd ed.
32. Politis M., et al. Imaging of microglia in patients with neurodegenerative disorders. Front. Pharmacol. 2012, 3:96.
33. Reiner A., et al. Differential loss of striatal projection neurons in Huntington disease. PNAS 1988, 85:5733-5737.
34. Richfield E.K., et al. Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci. Lett. 1991, 132:121-126.
35. Richfield E.K., et al. Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann. Neurol. 1995, 38:852-861.
36. Rosenblatt A., Leroi I. Neuropsychiatry of Huntington's disease and other basal ganglia disorders. Psychosomatics 2000, 41:24-30.
37. Sapp E., et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 2001, 60:161-172.
38. Sidoryk-Wegrzynowicz M., et al. Role of astrocytes in brain function and disease. Toxicol. Pathol. 2011, 39:115-123.
39. Sofroniew M.V. Reactive astrocytes in neural repair and protection. Neuroscientist 2005, 11:400-407.
40. Storey E., Beal M.F. Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain 1993, 116:1201-1222.
41. Streit W.J., et al. Reactive microgliosis. Prog. Neurobiol. 1999, 57:563-581.
42. Thompson P.D., et al. The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain 1988, 111:223-244.
43. Tomiyama K., et al. Phenotypic disruption to orofacial movement topography in conditional mutants with generalised CamKIIa/Cre D1Tox versus striatal-specific DARPP-32/Cre D1Tox ablation of D1 dopamine receptor-expressing cells. Synapse 2011, 65:835-842. [Epub ahead of print].
44. Turjanski N., et al. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 1995, 118:689-696.
45. von Horsten S., et al. Transgenic rat model of Huntington's disease. Hum. Mol. Genet. 2003, 12:617-624.
46. Wake H., et al. Microglia: actively surveying and shaping neuronal circuit structure and function. Trends Neurosci. 2013, 36:209-217.
47. Wild E.J., Tabrizi S.J. Huntington's disease phenocopy syndromes. Curr. Opin. Neurol. 2007, 20:681-687.
48. Young A.B., et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 1986, 36:244-249.
49. Yung K.K.L., et al. Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 1995, 65:709-730.